Switch to
View more

Alkem Laboratories Ltd

ALKEM
Health CarePharmaceuticals
MidcapWith a market cap of ₹34,960 cr, stock is ranked 146
Low RiskStock is 1.32x as volatile as Nifty
2,935.9512.00 (+0.41%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
MidcapWith a market cap of ₹34,960 cr, stock is ranked 146
Low RiskStock is 1.32x as volatile as Nifty

Key MetricsEdit

PE RatioPE Ratio
21.24
PB RatioPB Ratio
3.95
Dividend YieldDiv. Yield
1.16%
Sector PESector PE
34.97
Sector PBSector PB
4.41
Sector Div YldSctr Div Yld
0.91%

Forecast & RatingsDetailed Forecast 

52%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Pro Only

Earnings

Earnings Growth

Pro Only

Revenue

Rev. Growth

Pro Only

See Detailed Forecast

Company Profile

Alkem Laboratories Limited is engaged in the development, manufacture and sale of pharmaceutical and neutraceutical products.

Brands

Alkem Labs

Pharmaceutical company

Investor PresentationView older 

Aug 5, 2022

PDF
View Older Presentations

Brands

Alkem Labs

Pharmaceutical company

Financial TrendFinancial statements 

20192020202120227.448.459.1010.800.761.131.591.65
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Retirement 
Announced OnAug 18, 2022

Alkem Laboratories Limited has informed the Exchange about retirement of Balmiki Prasad Singh as Executive Director of the company w.e.f. 25-Aug-2022 | Download

Alkem Laboratories Limited has informed the Exchange about retirement of Balmiki Prasad Singh as Executive Director of the company w.e.f. 25-Aug-2022 | Download

Schedule of Analysts/Institutional Investor Meet/Con. Call 
Announced OnAug 17, 2022

Alkem Laboratories Limited has informed the Exchange about Schedule of Analysts/Institutional Investor Meet/Con. Call | Download

Alkem Laboratories Limited has informed the Exchange about Schedule of Analysts/Institutional Investor Meet/Con. Call | Download

Cash Dividend 
Ex. DateAug 8, 2022

Final • Div/Share: ₹ 4

See all events